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Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
Polyphenols have tumoricidal effects via anti-proliferative, anti-angiogenic and cytotoxic
mechanisms and have recently been demonstrated to modulate the immune response
through their anti- or pro- oxidant activity. Nevertheless, it remains controversial whether
antioxidant-rich supplements have real beneficial effects on health, especially in complex
diseases such as cancer. We previously identified a polyphenol-rich extract obtained
from Caesalpinia spinosa (P2Et) with anti-tumor activity in both breast carcinoma and
melanoma. The present work evaluated the ability of P2Et extract to modulate the
immune system in either the steady state or following tumor challenge. We found
that the prophylactic treatment of healthy mice increased the number of CD4+ and
CD8+ activated T, NK, regulatory T, dendritic and myeloid-derived suppressor cells in
lymphoid organs together with a significant increase in plasma IL-6. Interestingly, this
pre-conditioning of the host immune system with P2Et did not involve a protective
effect against the control of tumor growth and metastasis in transplantable models
of melanoma (B16) and breast cancer (4T1), but in contrast, a detrimental effect
was observed in both models. We further demonstrated that this effect was at least
partly due to an increase in regulatory T cells, myeloid-derived suppressor cells, and
proinflammatory cytokines, with a concomitant decrease in CD4+ and CD8+ T cells.
Taken together, these results suggest that the anti-tumor and immunomodulation
properties of the P2Et extract critically depend on the presence of the tumor andmight be
mediated by the complex interactions between the tumor cells and the other components
of the tumor microenvironment.
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INTRODUCTION
Cancer is a major public health problem and remains one of the major causes of mortality
and morbidity worldwide despite major advances in treatment. In addition to surgery, cancer
therapy includes chemotherapy and radiotherapy, which may cause severe off-target toxicity and
are not equally effective in all patients. The identification of the immune system as a key player
in the control of tumor growth and progression recently led to the development of different
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immunotherapy strategies, such as cancer vaccines, immune
modulator antibodies and adoptive cell transfer therapy (1).
Despite resounding clinical successes, immunotherapy has
shown durable clinical benefit only in a certain proportion of
patients. Consequently, a search for alternative treatments or
combined strategies against cancer remains necessary (2).
Natural products, which are acquiring increasing importance,
can prevent tumor development due to their antioxidant, anti-
proliferative, anti-angiogenic and immune modulator properties
(3–5). Nevertheless, the health benefits of consuming antioxidant
supplements remain controversial since some studies have shown
advantages (6–9) but others consider them detrimental (10–13).
In this context, supplements with vitamin E and N-acetylcysteine
(NAC) have been shown to lead to greater progression of
lung cancer (14) and increased melanoma metastasis formation
(15). Previously, our group identified a gallotannin-rich extract
from Caesalpinia spinosa (P2Et) as an anti-tumor agent in
breast and melanoma murine models (16–18). This extract
contains high proportions of gallic acid-containing compounds
(galloylquinic acids and glucosyl-gallate compounds), shows
important antioxidant activity and is highly and specifically
cytotoxic against tumor cells, in particular those expressing drug
resistance pumps such as Pgp (19). Furthermore, the anti-tumor
activity of P2Et requires an intact adaptive immune system in the
B16F10 melanoma model (16).
In this study, we assessed the capacity of the P2Et extract
to modulate the immune system in either the steady state or
following tumor challenge. We observed that P2Et indeed has
immune modulatory properties when administered to healthy
mice. However, in contrast to its anti-tumor activity in tumor-
bearing mice, prophylactic treatment with P2Et led to enhanced
tumor growth of engrafted breast and melanoma tumors. This
effect was at least partly due to the increased production of
IL-6. Taken together, these results suggest that the anti-tumor
activity and immune modulation properties of the P2Et extract
critically depend on the presence of the tumor and might be
mediated by the complex interactions between tumor cells and
other components of the tumor microenvironment.
MATERIALS AND METHODS
Plant Material
Caesalpinia spinosa pods were collected in Villa de Leyva,
Boyacá, Colombia and identified by Luis Carlos Jiménez from
the Colombian National Herbarium (voucher specimen number
COL 523714, Colombian Environmental Ministry agreement
number 0454 related to the use of genetic resources and derived
products). The P2Et extract was produced under GMP conditions
and chemically characterized as previously described (19, 20).
Mice
Young (6–12 weeks old) female C57BL/6 and BALB/c mice were
purchased from the Jackson Laboratories (Bar Harbor, ME, USA)
and housed at the animal facilities of the Pontificia Universidad
Javeriana (PUJ, Bogotá, Colombia) following the established
protocols of the Ethics Committee of the Faculty of Sciences,
PUJ, and National and International Legislation for Live Animal
Experimentation (Colombia Republic, Resolution 08430, 1993;
National Academy of Sciences, 2010). The present study was
approved by the ethics committee of the Faculty of Sciences,
PUJ, on May 6, 2012. Each specific protocol was also approved
by the animal experimentation committee of PUJ. Mice were
maintained in polyethylene cages with food and water provided
ad libitum, on a 12-h light/dark cycle at 20–22◦C and 40–60%
humidity. The Tyr::NRas mice were breed with INK4a knockout
mice to obtain the Tyr-NRasQ61k::Cdk4R24C spontaneous mouse
melanoma model. The breeding and experiments with Tyr-
NRasQ61k::Cdk4R24C mice were performed at the animal facility
(Epalinges) of the University of Lausanne where the colonies
are established. This model was tested under the approval of
the Veterinary authority of Canton of Vaud, Switzerland and
under authorization VD1850. Experiments were performed in
accordance with Swiss ethical guidelines.
Tumor Cell Lines and Culture Conditions
The murine melanoma B16F10 cell line was kindly provided
by PR (Ludwig Center for Cancer Research, Department of
Oncology—Faculty of Biology and Medicine University of
Lausanne, Switzerland). The B16 mouse model was created in
the 1970s from a melanoma that developed spontaneously in
the ear of a female C57BL/6 mouse and was then passaged in
vivo to create the B16F10 line (21). The murine breast cancer
4T1 cell line was grown in BALB/c mice and developed into a
highly tumorigenic and invasive tumor that can spontaneously
metastasize from a primary tumor in the mammary gland
to multiple distant sites (22). The 4T1 mammary tumor
cells were kindly provided by Dr Alexzander Asea (Texas
A&M Health Science Center College of Medicine, Temple,
TX). Cells were cultured in RPMI-1640 (Eurobio, Toulouse,
France) supplemented with 10% heat-inactivated fetal bovine
serum (FBS) (Eurobio), 2mM L-glutamine, 100 U/ml penicillin,
100µg/ml streptomycin, 0.01MHEPES buffer and 1mM sodium
pyruvate (Eurobio) and incubated in a humidified environment
at 37◦C and 5% CO2. Cells were grown until 75% confluency and
passaged using trypsin/1X EDTA (Eurobio), washed with PBS
and resuspended in supplemented RPMI-1640.
Abs
The following Abs were used for cell surface staining: anti-
CD3 Pacific Blue (clone 17A2), anti-CD8 PE Texas Red (clone
53.6.7), anti-CD44 PE-Cy7 (clone IM7), anti-B220 PE Texas
Red (clone RA3-6B2), anti-NK1.1 FITC (clone PK136), anti-
CD69 Alexa Fluor 647 (clone H1-2F3), anti-Ly6C APC-Cy7 (AL-
21), anti-Ly6G PE-Cy7 (clone 1A8) (Biolegend, San Diego, CA,
USA), anti-CD4 APC e-Fluor 780 (clone GK1.5), anti-CD62L
PE-Cy5 (clone MEL-14) (eBiosciences, San Diego, CA, USA),
anti-CD45RB PE (clone 16A), anti-CD3 Alexa Fluor 647 (clone
17A2), anti-CD4 PerCP (clone RM4-5), anti-CD8 PE (clone 53-
6.7), anti-CD45 PE-Cy5 (clone 30-F11), anti-CD45 PE (clone 30-
F11), anti-CD11c FITC (clone HL3) and anti-CD11b Alexa Fluor
700 (clone M1/70) (BD Biosciences, San José, CA, USA). The
abs for intracellular staining included anti-FoxP3 Alexa Fluor
488 (clone MF23), anti-IFNγ Alexa Fluor 700 (clone XMG1.2),
TNFα PE-Cy7 (clone MP6-XT22), IL-2 FITC (clone JES6-5H4)
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(BD Biosciences) and anti-CTLA-4 PE (clone UC10-4F10-11)
(Biolegend). A LIVE/DEAD Fixable Aqua Dead Cell Stain Kit
(InvitrogenMolecular Probes, Eugene, OR)was used for dead cell
exclusion.
In vivo Tumor Development Experiments
and Treatment
For melanoma tumor induction, C57BL/6 mice were
subcutaneously (s.c.) inoculated in the right flank with 1 ×
105 viable B16F10 cells suspended in 100 µl of PBS. For the
breast cancer murine model, 1 × 104 viable 4T1 cells suspended
in 100 µl of PBS were s.c. injected into the right mammary fat
pad of BALB/c mice. To evaluate the effect of P2Et treatment on
tumor growth, 3 days after B16F10 inoculation, PBS (negative
control) or P2Et extract (75 mg/kg body weight in 200 µl of
PBS) were s.c. administered around the tumor two times per
week. The P2Et therapeutic dose used was 4-fold lower than the
LD-50 (median lethal dose) to ensure low toxicity. To determine
whether P2Et modulates the immune response in healthy
C57BL/6 or BALB/c mice, the animals were intraperitoneally
(i.p.) injected with P2Et or PBS two times per week for 21
(C57BL/6) or 32 (BALB/c) days. To evaluate the effect of P2Et
on tumor growth in a spontaneous melanoma model (23), Tyr-
NRasQ61k::Cdk4R24C mice were used (24). These mice were first
synchronized for the appearance of melanoma tumors by topical
treatment with the carcinogen DMBA on a shaved zone of the
back, once per week for 5 weeks (100µl of 0.5 mg/ml in acetone).
Treatment was initiated at week 4 after birth. Tumors started
to appear 9 weeks after the first DMBA treatment, and the mice
started P2Et treatment (75 mg/kg) twice per week as soon as the
tumors were visible until the end of the experiment. To evaluate
the effect of P2Et as prophylactic therapy in both murine models,
mice received the following treatment scheme: PBS injection
→ tumor cells→ PBS injection (PBS/PBS), PBS injection→
tumor cells→ P2Et treatment (PBS/P2Et), and P2Et treatment
→ tumor cells → P2Et treatment (P2Et/P2Et). In all cases,
the pretreatment was i.p administered two times per week for
10 days, followed by the injection of B16F10 or 4T1 cells, and
finally, 3 days after tumor cell injection, the post-treatment was
s.c. administered around the tumor two times per week for 21
and 32 days, respectively (Figure 1). In all experimental settings,
the size of the tumors was assessed three times per week with
Vernier calipers, and the volume was calculated according to
the formula V (mm3) = L (major axis) × W2 (minor axis)/2
(25). Mice were euthanized by CO2 inhalation, and then spleen,
draining inguinal lymph nodes (LN), and tumor were removed.
Tumor weight was determined using a high-sensitivity balance.
Flow Cytometry and Intracellular Cytokine
Staining Assays
Single cell suspensions were obtained from spleen, LN and tumor
by mechanical or enzymatic dissociation. Briefly, 1 × 106 cells
were stained with LIVE/DEAD Fixable Aqua for 20min in the
dark at room temperature. After washing with PBS 2% FBS, the
cells were stained for 30min at 4◦C in the dark with surface
antibodies according to the designed multicolor panels. Then,
the cells were washed and resuspended in 300 µl of PBS 2%
FBS. To identify regulatory T cells, cells previously marked
with anti-CD4 and anti-CD3 were fixed, permeabilized and
stained with anti-FoxP3 and anti-CTLA-4 antibodies for 30min
at room temperature in the dark. The cells were then washed and
resuspended in 300 µl of PBS 2% FBS.
To evaluate the functional activity of spleen cells from healthy
mice after P2Et treatment, 2 × 106 splenocytes were cultured
with 3µg/mL of P2Et extract or EtOH as a control for 24 h at
37◦C and 5% CO2. The cells were then cultured with phorbol
12-myristate 13-acetate (PMA) and ionomycin (P/I) or without
a stimulus for 7 h. The last 6 h of culture were performed in the
presence of brefeldin A (1µg/ml) (BD Pharmingen). Briefly, the
cells were stained with LIVE/DEADFixable AquaDeadCell Stain
for 20min in the dark at room temperature. After washing with
PBS 2% FBS, the cells were stained for 30min at 4◦C in the dark
with anti-CD3, anti-CD4, anti-CD8 and anti-CD45 antibodies.
Later, the cells were washed, fixed and permeabilized and then
stained with anti-IFNγ, TNFα and IL-2 for 30min at 4◦C in the
dark. Finally, the cells were washed and resuspended in 300 µl
of PBS 2% FBS. Cells were acquired by flow cytometry using
a FACSAria II flow cytometer (BD Immunocytometry Systems,
San José, CA, USA), and the results were subsequently analyzed
using FlowJo 9.3.2 software (Tree star, Ashland, OR). Pie charts
were represented using Pestle version 1.7 and SPICE version 6.0
software (the National Institutes of Health, Bethesda, MD) (26).
Cytokine Assay
Serum was prepared from blood obtained by cardiac puncture,
and cytokine evaluation was performed using a Cytometric
Bead Array (CBA) mouse Th1, Th2, Th17 cytokine kit
(BD Biosciences) according to the manufacturer’s instructions.
Experiments were performed twice, and each experiment was
performed in duplicate. Events were acquired using a FACSAria
II flow cytometer (BD Immunocytometry Systems), and the
results were subsequently analyzed using FCAP array software
version 3.0 (BD Biosciences). Data were log-transformed and
plotted as the mean± SEM.
Cell-Based Antioxidant Activity Assay
Splenocytes fromC57BL/6 and BALB/c healthymice were seeded
at a density of 2 × 105/well on a 96-well microplate in 200
µl medium/well at 0, 1 or 10µM H2O2 (Sigma). Two hours
after treatment, the medium was removed, and the cells were
incubated with EtOH, 10µM or 100µM Trolox (Sigma), and
3 or 30µg/ml of P2Et. 12 or 24 h after treatments, medium
was removed, and the cells were washed twice with 200 µl of
1X PBS. Then, the cells were incubated for 40min at 37◦C
with 100µl/well of 1µM7′-dichlorofluorescin diacetate (DCFH-
DA) in Hank’s Balanced Salt Solution (HBSS) buffer. Cells were
washed with 100 µl of 1X PBS and resuspended in 200 µl
of 1X PBS containing propidium iodide. Cells were acquired
by flow cytometry using a FACSAria II flow cytometer (BD
Immunocytometry Systems, San José, CA, USA), and the results
were subsequently analyzed using FlowJo 9.3.2 software (Tree
star, Ashland, OR).
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FIGURE 1 | Experimental treatment scheme. To evaluate the effect of P2Et as prophylactic therapy in both murine models, mice received the following treatment
scheme: PBS injection→ tumor cells→ PBS injection (PBS/PBS), PBS injection→ tumor cells→ P2Et treatment (PBS/P2Et), and P2Et treatment→ tumor cells
→ P2Et treatment (P2Et/P2Et). The pretreatment was administered via i.p two times per week for 10 days, the tumor was later established by injection of B16F10 or
4T1 cells, and finally, 3 days after tumor cell injection, the post-treatment was s.c. administered around the tumor two times per week for 21 and 32 days, respectively.
Statistical Analysis
Statistical analysis of the significance between two groups was
calculated using the Mann–Whitney U test. For all cases, the
differences were considered statistically significant when p <
0.05. GraphPad Prism version 6.0 for Mac OS X statistics
software (GraphPad Software, San Diego, CA) was used for the
statistical analyses. The pie charts were compared using 10,000
permutations calculated with the software SPICE version 6.0.
RESULTS
The Anti-tumor Effect of P2Et Is Lost When
Administered as Prophylactic Treatment
We have previously described that P2Et treatment post-
tumor engraftment delays both melanoma and breast cancer
tumor growth (16–18). We wanted to assess whether P2Et
as prophylactic treatment could prevent tumor growth. To
answer to this question, we treated mice with P2Et or PBS
(control) for 10 days 2 times per week, prior to engraftment
of either 1 × 105 B16F10 or 1 × 104 4T1 cells. Subsequently,
P2Et or PBS administration s.c. in the periphery of the tumor
was continued (Figure 1). In the melanoma B16 model, we
confirmed that therapeutic treatment of established tumors
with P2Et led to significantly delayed tumor growth compared
with the other groups. Strikingly, however, this anti-tumor
effect was lost when a prophylactic P2Et treatment was
added, as shown by rapid tumor growth in all mice in the
P2Et/P2Et group (Figures 2A,B). In the 4T1 breast cancer
model, therapeutic treatment with P2Et also delayed tumor
growth in PBS/P2Et mice (Figures 2C,D). Interestingly, the
addition of prophylactic P2Et treatment showed a different
pro-tumoral effect compared with B16 tumors. Indeed, the
growth of the primary 4T1 tumors was slower than in the
PBS group, but the frequency of metastasis was higher both
in terms of incidence and number of organs invaded by 4T1
tumor cells (Figures 2E,F), which necessitated the euthanasia
of these mice 12 days before the other groups (Figures 2C,D).
Moreover, a higher proportion of both mice and organs were
affected in the P2Et/P2Et treatment group compared with
the PBS/PBS or PBS/P2Et groups at day 32 after grafting
(Figures 2E,F). Indeed, only three mice from the PBS/P2Et
group had visible metastases, and only 3 organs were affected
(Figure 2F).
To evaluate the possibility that prophylactic treatment
with the P2Et extract could directly act on T cells and
inhibit their functional capacity, we treated spleen cells
from C57BL/6 and BALB/c healthy mice with P2Et for
24 h, and cytokine production of T cells was assessed after
PMA/ionomycin stimulation. We found that P2Et extract
did not directly affect the functional capacity of T cells
from C57BL/6 (Supplementary Figures 1A,B) or BALB/c
(Supplementary Figures 1C,D). These results suggested that
the unexpected findings regarding overgrowth or increased
metastatic ability of tumor cells in P2Et/P2Et mice in both
models might be due to indirect effects on other components of
the tumor microenvironment. In this sense, we evaluate the effect
of P2Et over the oxidative stress of splenocytes from healthy
mice. For this, the cells were cultured for 2 h with medium
(basal) or with H2O2 to induce oxidative stress. It was found
that P2Et, like Trolox, has antioxidant activity in splenocytes
from BALB/c (Supplementary Figures 2A,B) and C57BL/6
(Supplementary Figures 2C,D) healthy mice in basal and
oxidative stress conditions. Additionally, this antioxidant effect
was observed both at 12 (Supplementary Figures 2A,C) and
24 h (Supplementary Figures 2B,D), and it was dose depended.
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FIGURE 2 | In vivo P2Et treatment delays melanoma and breast tumor growth, but this effect is lost when P2Et pretreatment is also provided. (A) B16F10 individual
tumor volumes for all groups. (B) B16F10 tumor growth curve. (C) 4T1 individual tumor volumes for all groups. (D) 4T1 tumor growth curve. (E) 4T1 frequency of
metastasis among the different groups. (F) Distribution of multi-organ metastasis of 4T1 tumors for all groups. n corresponds to the number of mice with metastases.
In all cases, data are represented as the mean ± SEM. The p values were calculated using a Mann-Whitney U test. *p < 0.05, **p < 0.01.
These results show that P2Et can protect normal splenocytes
from oxidative aggression.
Prophylactic P2Et-Based Therapy Is
Associated With the Generation of an
Immunosuppressive Microenvironment
That Promotes Tumor Growth
To determine whether P2Et treatment pre- and post-engraftment
induces changes in murine immune system reactivity, the
frequency and distribution of different cell populations from
spleen, lymph nodes (LN) and tumors of both murine
models were evaluated comparing mice administered or not a
prophylactic course of P2Et. Both in the B16F10 and 4T1 murine
models, P2Et/P2Et mice had fewer CD45+ cells in the draining
lymph nodes than the control group (Figure 3A). Likewise, this
difference was also observed when we evaluated CD3+, CD4+,
and CD8+ T cells in B16F10 and 4T1 LN of tumor-bearing mice
(Figure 3B). We also found a reduced number of activated T cells
(CD44+) in draining LN of B16F10 tumors, while no differences
were observed in the 4T1 model, (Figure 3C). In the tumor, we
observed an increase in CD45+ tumor-infiltrating cells in the
PBS/P2Et group in both models (Figure 3D), which appeared to
be CD3+, CD4+, or CD8+ T cells (Figure 3E) and were also
more activated (Figure 3F), compared with the control group.
Although the differences were not clear in terms of memory
cell subpopulations from the tumor (Figure 3G), it was clear
that P2Et/P2Et mice in 4T1 had a higher, but not significant,
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frequency of CD4+ naïve (TN, CD45RB
+, CD62L+) T cells
but a lower frequency of CD4+ effector memory T cells (TEM,
CD45RB−, CD62L−) than the PBS/P2Et group (Figure 3G).
Likewise, P2Et/P2Et mice had higher frequencies of naïve CD8+
T cells and lower frequencies of CD8+ TEM cells (Figure 3G).
In addition, the PBS/P2Et group had more CD8+ T cells than
regulatory T cells in B16 tumors, which may favor the tumor
control. This favorable CD8/Treg ratio was not observed in
4T1 tumors (Figure 3H), suggesting that the strain, as well as
the type of tumor, may be at the origin of these differences.
The assessment of other immune cell populations in the tumor
showed that in both models, the P2Et/P2Et groups had increased
proportions of tumor-infiltrating MDSC-LC (27) and a higher
number of CD4+ and CD8+ T cells than the other groups
(Figure 3I).
Interestingly, a significant increase in the serum
concentrations of TNF and IL-6 was found in the P2Et/P2Et
groups compared with the other groups in both tumor models
(Figures 4A,B), while in the P2Et/P2Et-treated B16 tumors, the
serum concentrations of both IL-17 and IL-4 were significantly
decreased (Figure 4A).
The P2Et Extract From Caesalpinia spinosa
Modulates the Immune Response in
Healthy C57BL/6 and BALB/c Mice
To ascertain whether the presence of a tumor was necessary
for the effects of the P2Et extract on the immune system,
we measured the serum levels of Th1/Th2/Th17 cytokines and
assessed the distribution of several immune cell populations in
healthy C57BL/6 mice treated with P2Et. Treatment with P2Et
two times per week for 21 days increased the numbers of CD8+ T
cells (Figure 5A) and the frequency of activated CD4+ and CD8+
T cells in the spleen compared with the control mice (Figure 5B).
Moreover, mice treated with P2Et showed more CD4+ TEM cells
in spleen and LN and fewer TN cells and central memory (TCM,
CD45RB−, CD62L+) CD4+ T cells in spleen compared with the
control group (Figure 5C). However, no differences were found
in CD8+ T cells subsets (Figure 5C). Furthermore, we observed
increased numbers of total NK and CD69+ activated NK cells
(Figure 5D) along with more regulatory CTLA4+, Foxp3+ T
cells (Treg) in the spleen of P2Et-treated mice (Figure 5E).
However, the ratio of CD8+/Treg cells was the same in mice with
or without treatment (Figure 5F), suggesting that P2Et might
favor the mobilization of CD8+ cells to the spleen. Dendritic
cells (DCs) were increased in the spleen of P2Et-treated mice
(Figure 5G) as well as MDSC-LCs, which were increased in both
spleen and LN (Figure 5H). Moreover, P2Et-treated mice had
increased serum concentrations of IL-10, IL-17, IFN-γ, IL-6, IL-4,
and IL-2 compared with the control group (Figure 5I).
To study possible strain specificity for the response to P2Et,
we also evaluated the effect of the extract in healthy BALB/c
mice. P2Et induced significant increases in CD3+ and CD8+
T cell numbers and tended to increase the number of CD4+ T
cells in spleen (Figure 6A). However, no differences were found
in LN (data not shown). In addition, P2Et treatment induced
higher numbers of activated CD44+ CD4+ and CD8+ T cells
in the spleen and LN (Figure 6B), as well as effector CD4+ and
CD8+ T cells in the spleen (Figure 6C). As observed for C57BL/6
mice, higher numbers of Tregs were found in the spleen from
P2Et-treated mice (Figure 6D), but the CD8+/Treg ratio was
not affected (Figure 6E). Conventional DCs were also increased
in spleen and LN after P2Et treatment in comparison to the
control group (Figure 6F); however, the MDSC-LC population
increased in spleen but significantly decreased in LN (Figure 6G).
In terms of cytokine production, mice treated with P2Et had only
higher concentrations of IFN-γ and IL-6 in serum compared
with C57BL/6, in which a more diverse profile was observed
(Figure 6H). Taken together, these results showed that P2Et
administration modulated the immune system already in tumor-
free, healthy C57BL/6 and BALB/c mice, mainly at a systemic
level, even if changes in the LN were only observed in the BALB/c
strain. These differences could be explained by the genetic
background and might be determinants of when the P2Et extract
was used as a treatment. The finding that the P2Et extract has
an immunomodulatory effect in C57BL/6 and BALB/c healthy
mice suggests that P2Et extract administration, upon tumor
engraftment, modifies the tumor microenvironment, making it
more proinflammatory and/or immunosuppressive, which in
turn may promote faster tumor growth.
In vivo P2Et Treatment Delays Tumor
Growth in the Spontaneous Tyr::N-Ras
Melanoma Model
Since P2Et administration induces activation of the immune
system in healthy mice and can retard B16F10 tumor growth
(16), and the prophylactic treatment seems to have a pro-
tumoral rather than anti-tumoral effect, we wondered what
would happen in the context of a spontaneous tumor model,
a setting more closely resembling the clinical situation than
transplantable tumor models. To address this question, we
treated mice bearing spontaneous Tyr::N-RasQ61KxINK4a-/-
engineered melanomas, referred to thereafter as Tyr::Nras (23).
The Tyr:N-Ras transgenic mice developed melanoma tumors
9 weeks after DMBA topic treatment. P2Et therapy initiated
immediately after tumor detection was able to delay tumor
growth (Figure 7A). In addition, P2Et-treated mice showed a
trend toward higher survival rates compared with the littermate
control mice (Figure 7B). These findings indicate that P2Et-
therapy still exerts a protective role in spontaneous melanoma
tumors at a stage when immune tolerance and tumor-escape
likely occurred.
DISCUSSION
Polyphenols are widely present in food and beverages of plant
origin. Numerous studies have focused on the antioxidant
properties of polyphenols, but the beneficial effect of antioxidants
in vivo remains controversial (28). Despite years of research, the
value of antioxidants in the prevention and treatment of cancer
is not yet clear, and it could not yet be determined whether
antioxidants act as protective or pro-tumorigenic agents. These
inconsistencies appear to be due tomultiple factors, including the
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FIGURE 3 | P2Et pretreatment decreases T cell recruitment into the tumor induced after P2Et post-engraftment therapy. Fold change in total LN cells numbers (A) in
CD3+, CD4+, and CD8+ T cells (B) and in CD44+ activated T cells (C) in both tumor models and all groups. Fold change in CD45+ cell numbers per mg of tumor,
(D) CD3 +, CD4 +, and CD8+ T cells (E), and activated CD44+ T cells (F) in both models and all groups. Percentage of CD4+ and CD8+ T cells with naive, TCM,
TEM, and TTE phenotypes in tumors (G). Tumor ratio of CD8
+ T cells/Treg (H). Pie charts of the distribution of tumor-infiltrating populations in each group (I). In all
cases, data are represented as the mean ± SEM. The p values were calculated using a Mann-Whitney U test. *p < 0.05, **p < 0.01.
dose and type of antioxidant, route of administration and tumor
type (29).
In this study, we not only confirmed our previous
observations (16) and, additionally, observed a decrease in
MDSC-LC after P2Et treatment, but we also showed that this
immunostimulating effect was reversed when we used P2Et
as a prophylactic treatment, apparently at the expense of a
systemic pre-activation of the immune system that induced a
proinflammatory environment. The interesting thing is that
P2Et exerts an antioxidant effect at a basal level and after stressor
treatment which does not change the cytokine profile produced
by normal splenocytes of both BALB/c and C57BL/6 after
stimulation with PMA/ionomycin (Supplementary Figures 1,
2). This means that the generation of a pro-inflammatory
environment evidenced in the plasma of healthy animals,
possibly depends on the complex interactions between the
immune system and its microenvironment, which is different
in animals with tumors, where this proinflammatory activity
is increased. Likewise, it has been found that the P2Et extract
has antioxidant activity in tumor cell lines such as B16 and
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FIGURE 4 | In vivo pre- and post-P2Et treatment favors the production of proinflammatory cytokines. Cytokine levels in the serum of B16 tumor-bearing mice (A) or
4T1 tumor-bearing mice (B) with PBS/PBS, PBS/P2Et or P2Et/P2Et treatment. The data were log-transformed and plotted as the mean ± SEM. The p values were
calculated using a Mann-Whitney U test. *p < 0.05, **p < 0.01.
FIGURE 5 | P2Et treatment modulates the immune response in healthy C57BL/6 mice. (A) Absolute numbers of CD3+, CD4+ and CD8+ T cells in spleen from
healthy mice treated with P2Et or PBS (control). (B) Splenic CD4+ and CD8+ T cells expressing the CD44+ marker. (C) Percentages of the different populations
(naive, TCM, TEM and TTE) of splenic CD4
+ and CD8+ T cells in mice with or without treatment. Absolute numbers of splenic NK and CD69-expressing NK cells (D)
and regulatory T cells (E) in healthy mice treated with P2Et or PBS (F). Ratio of splenic CD8+/Treg cells. (G) Conventional splenic DC numbers in each group. (H)
Absolute numbers of MDSC-LCs in lymph nodes and spleen. (I) Cytokine concentration in serum of PBS or P2Et-treated healthy C57BL/6 mice measured by CBA. In
all cases, the data are represented as the mean ± SEM. The p values were calculated using a Mann-Whitney U test. *p < 0.05, **p < 0.01, ***p < 0.001.
K562 cells (unpublished data), however, this antioxidant activity
does not protect them from apoptotic cell death (20), and
combined treatment with P2Et and doxorubicin, of BALB/c
mice ortotopically transplanted with breast cancer TSA cell line,
significantly diminish tumor evolution compared with isolated
treatment (19).
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FIGURE 6 | P2Et extract modulates the immune response in healthy BALB/c mice. (A) Absolute numbers of splenic CD3+, CD4+, and CD8+ T cells in healthy mice
treated with P2Et extract or PBS (control). (B) CD44+ CD4+ and CD8+ T cells in spleen or LN. (C) Percentages of splenic CD4+ and CD8+ T cells with naive, TCM,
TEM and TTE phenotypes. (D) Absolute numbers of splenic regulatory T cells. (E) Ratio of splenic CD8
+/Treg cells. (F) Conventional DC numbers in spleen or LN in
each mouse group. (G) Absolute numbers of MDSC-LCs in lymph nodes and spleen. (H) Cytokine concentrations in serum of PBS or P2Et-treated healthy BALB/c
mice measured by CBA. In all cases, data are represented as the mean ± SEM. The p-values were calculated using a Mann-Whitney U test. *p < 0.05, **p < 0.01.
As recently reviewed, the protective effects of green tea, as
well as its main polyphenol, the epigallocatechin gallate (EGCG),
have been demonstrated in various studies, including (1) tumor
development, as revealed in a 10-year prospective cohort
study, (2) the prevention of colorectal adenoma recurrence,
as observed in a double-blind randomized clinical phase II
trial, (3) inhibition of metastasis of B16 melanoma cells to the
lungs of mice, and (4) synergistic enhancement of anticancer
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FIGURE 7 | In vivo P2Et treatment delays tumor growth in the spontaneous Tyr::Nras melanoma model. (A) Tumor growth curve of Tyr:N-RasQ61K transgenic mice
treated with PBS or P2Et. Data are represented as the mean ± SEM. (B) Kaplan-Meier survival curves of Tyr::N-Ras transgenic mice treated with PBS (n = 7) or P2Et
(n = 8). The differences between groups in tumor growth and survival were not statistically significant.
activity against human cancer cell lines combining EGCG and
anticancer compounds (30). Additionally, some polyphenols,
such as resveratrol and curcumin, can modulate the immune
response by decreasing TGFγ production and the accumulation
of Tregs, thus restoring antitumor immunity (31, 32). Moreover,
in aged rats, polyphenols derived from Cassia auriculata flowers
have been shown to increase the frequencies of T and B cells
and enhance splenocyte proliferation (33). Likewise, the extracts
of ripe fruits from date palm increased the number of IFNγ+
CD4+ cells in the spleen of C3H/HeN mice (34), suggesting an
immunostimulating effect of polyphenols.
In contrast to these data, in a non-tumoral context,
polyphenols seem to have different functions. In fact, EGCG
and a green tea extract containing 10µM of EGCG induce IL-
10 production and FoxP3 expression in Jurkat T cells in vitro
and increase Treg frequencies in vivo in healthy BALB/c treated
daily for 7 days (35). Interestingly, we also observed an increase
in Tregs in both strains of healthy mice in response to P2Et
treatment. However, the Treg population decreased when the
animals were treated with P2Et in a tumoral context, but different
results were obtained depending on the strain. These findings
suggest that the regulation of FoxP3 expression mediated by
polyphenols also depends on the genetic background.
Unexpectedly, pretreatment with P2Et favored tumor growth
and metastasis in both BALB/c and C57BL/6 mice. This effect
was related to a generalized decrease in CD4+ and CD8+ T cell
frequencies in the lymphoid nodes and tumor (in both tumor
models) and an increase in intratumoral MDSC-LCs compared
with the controls, as well as a significant increase in IL-6 plasma
levels in the animals.
Natural products, particularly tannic acid, have been
implicated in the decrease in proliferation of normal lymphocytes
and the production of IL-2 (36). However, a systematic review of
the literature examining the effects of flavonoids on the immune
response has shown that in the vast majority of studies, none of
the parameters of the immune response evaluated in the different
studies is affected in healthy individuals in response to prolonged
consumption or large amounts of natural antioxidants. It is
worth noting, however, that not many studies to date have
evaluated the multi-parametric (cytokines, innate and adaptive
immunity) roles of flavonoids in the modulation of the immune
response. Interestingly, the systematic review shows that there
was no effect on the reduction of TNF-α levels after intake of
meals or flavonoid-rich supplements in any of the interventional
studies conducted in healthy individuals (0/21). In contrast, in
individuals at high risk of cardiovascular disease, flavonoids were
found to decrease TNF-α levels in at least 30% of interventions
(5/17). This effect was much more pronounced if the analysis was
restricted to patients affected by different diseases, among which
60% of cases (4/7) showed an effective reduction of TNF-α values
after supplementation with different mixtures enriched with
polyphenols. Thus, it is possible that the influence of flavonoids
on immunity is more effective in individuals for whom the
presence of risk factors generated by the disease favors a greater
challenge to the immune response, compared to individuals with
a low degree of inflammation (37).
All the above findings raise the question of why
preconditioning of the immune response with the P2Et
extract favors tumor growth. It was recently found that the
antioxidants N-acetylcysteine (NAC) and vitamin E increase
the proliferation of human lung cancer cells and tumor growth
in mice with B-RAF– and K-RAS–induced lung cancer by
reducing ROS, DNA damage, and p53 (14). Additionally,
administration of N-acetylcysteine (NAC) increased lymph
node metastases in a spontaneous mouse model of malignant
melanoma but had no impact on the number and size of
primary tumors. Similarly, NAC increases the migration and
invasive properties of human malignant melanoma cells without
affecting their proliferation. This phenomenon is related to the
synthesis of glutathione, which suggests that the relationship
between antioxidants and glutathione play an important role
in melanoma progression (15). However, it is possible that the
antioxidant activity of polyphenols favor cellular proliferation
by removing some of the tumor cells from a state of senescence
induced by high levels of ROS, as described for some tumor
models (38).
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In contrast, some polyphenols, such as resveratrol, curcumin
and EGCG, negatively regulate the expression of coactivator
molecules. Particularly, resveratrol increases the expression
of suppressor molecules, such as inhibitory immunoglobulin-
including transcript −3 and −4 (ILT3, ILT4), and decreases
the ability to produce proinflammatory IL-12 after activation,
increasing the production of IL-10 upon stimulation with
LPS. Interestingly, curcumin-treated DCs show impaired
induction of Th1 responses (39). This suppression may
promote a tolerogenic microenvironment prior to the
appearance of a tumor, or in our model, prior to tumor
transplantation, limiting the in situ inflammatory process,
which is required for the generation of an effective immune
response.
Another important element that should be considered in
the use of polyphenols is the dose response effect. For
example, resveratrol has a biphasic effect, where it increases
the activity of cytotoxic T and NK cells at low concentrations
and inhibits their activities at high concentrations (40, 41).
Additionally, polyphenols seem to directly modulate CD4+ T
cell activation and polarization possibly through modulation
of the expression of CD28/CTLA-4. In fact, resveratrol and
curcumin are able to decrease CD28 and CD80 expression
and upregulate CTLA-4 and the IL-10 production (42). It is
possible that the pretreatment with P2Et in our tumor models
led to an accumulation of antioxidants, which finally decreased
the immune response and favored the development of the
tumor.
Another interesting result in the PBS/P2Et animals was the
observed lower numbers of intratumoral MDSC-LCs than in
the P2Et/P2Et-treated animals. The immunosuppressive activity
of MDSCs on T lymphocytes (43–46) and NK cells (47,
48) and the polarization toward a tumor-promoting type 2
phenotype (49) has been widely documented. It has been
reported that MDSCs can be targeted by antioxidants, which
limits the in vitro expansion of MDSCs as well as their
suppressive capacity (50, 51). However, MDSCs expand under
inflammatory conditions (52); the latter would allow us to
propose that the increase in proinflammatory cytokines in
healthy animals, (Figure 5I) as well as the significant increase
in IL-6 in tumor-bearing mice and mice pretreated with
P2Et (Figure 4) could act in concert to favor the deviation
of the immune response toward immunosuppression and be
translated into MDSC proliferation and recruitment, as has been
suggested in other models (53). The increase in IL-6 in animals
pretreated with P2Et could, in fact, be a consequence of the
pre-activation of the immune system and not a direct effect
of P2Et, since we observed that IL-6 decreased in response to
treatment with P2Et in the present work and in the 4T1 breast
cancer model in a previous study (18). In fact, the role of
polyphenols in the decrease of IL-6 production has been widely
reported (42), particularly through inhibition of the NF-κB
pathway involved in the synthesis of proinflammatory cytokines
(54).
The differences between the two models regarding the specific
response to the extract might be explained by the biological
differences in the strains in terms of their inflammatory profile,
as shown in other models (55). In addition, the biology of
tumors is different. The B16-F10 tumor model is considered
poorly metastatic, while the 4T1 breast cancer model is known
to be highly metastatic to several distant organs, as confirmed
by the larger number of metastatic foci at day 20 post-tumor
implantation.
Analysis of the P2Et activity in the spontaneous Tyr:NRas
model, the P2Et treatment started as soon as the tumors
appeared. At this time, the initial control phase exerted by the
immune response had failed, and the balance leaned thought
the tumor growth. It is in this context that the treatment
with P2Et improved the survival of the animals, possibly
because the tumor microenvironment of them was already
altered favoring the protective activity of P2Et. It would be
convenient to evaluate if the previous treatment for several
weeks before the tumor appears, is protective, and only in
this way could we sustain its preventive capacity, however, the
fact that it did not increase tumor growth is very favorable.
It would also be appropriate to assess the redox state of
the animal (or patient) before and after the onset of the
disease, to determine when the break REDOX balance, plays
in favor of the tumor growth or in favor of the immune
response.
Our results are in agreement with the idea that polyphenols,
particularly P2Et, can be used within the framework of anti-
tumor therapy, but not in a prophylactic context. Further
detailed studies are necessary to more precisely determine the
role of antioxidants in the immune response and, above all,
their protective or adjuvant role in the treatment of cancer.
The advent of new technologies that allow multiparameter
“omic” analysis involving the type of tumor, the genetic
characteristics of patients, as well as their oxidation status and
inflammatory profile, among others, are necessary to advance
the development of new therapies based on the use of natural
products.
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